The study validates the effectiveness of SmartBioSurface slides by testing them against standard charged glass controls. Results show that the nanocoated surface achieves more than double the initial attachment rate for cryopreserved human PBMCs. During testing, the slides demonstrated an average retention rate of approximately 98.5% after ten imaging cycles, with cell loss restricted to roughly 0.14% per cycle. Furthermore, the samples showed high stability, exhibiting no detectable loss after being stored at 4 °C for two weeks following fixation.

CEO Holger Neecke noted that the technology captures suspension-derived cells in a stable two-dimensional layer, overcoming a primary barrier to high-plex analysis. By mimicking the extracellular matrix, the slides allow researchers to study immune-cell interactions and circulating tumor cells while maintaining cellular morphology. This development offers a scalable solution for labs working in immuno-oncology and translational research, where integrating spatial profiling with liquid biopsy data is increasingly critical.